Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics, Safety and Efficacy of a New Gadolinium-based Contrast Agent, P03277, in Pediatric Patients From 2 to 17 Years of Age Undergoing Central Nervous System Contrast-enhanced MRI

NCT03749252 is registered in ClinicalTrials.gov with Guerbet as lead sponsor.

NCT NCT03749252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03749252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics, Safety and Efficacy of a New Gadolinium-based Contrast Agent, P03277, in Pediatric Patients From 2 to 17 Years of Age Undergoing Central Nervous System Contrast-enhanced MRI
Lead sponsor
Guerbet
Phase
Phase 2
Overall status
Completed
Start date
November 6, 2018
Completion date
August 10, 2020
Enrollment
80 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

body indication, central nervous system indication, pediatric patients